Valuation: Glaukos Corporation

Market Cap 10.69B 9.16B 8.59B 7.84B 14.8B 1,020B 14.95B 101B 39.43B 514B 40.15B 39.28B 1,703B P/E 2026 *
-224x
P/E 2027 * 617x
Enterprise Value 10.52B 9.01B 8.45B 7.72B 14.56B 1,003B 14.7B 99.63B 38.78B 506B 39.5B 38.64B 1,676B EV / Sales 2026 *
15.2x
EV / Sales 2027 * 12.3x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.29%
1 week-1.50%
Current month+8.80%
1 month+18.11%
3 months+50.87%
6 months+50.05%
Current year+60.65%
1 week 179.2
Extreme 179.2
191.62
1 month 145.78
Extreme 145.7759
191.62
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap.
19/08/26 Fiscal year

Director

7,500 0.0131%
11/08/26 Fiscal year

Chairperson

180,000 0.3139%
07/08/26 Fiscal year

Chief Financial Officer

60,000 0.1046%
Change 5-day change 1-year change 3-year change Capi.($)
-2.29%-1.50%+98.13%+145.52% 10.69B
+0.85%-0.24%-15.42%+18.87% 127B
+0.61%+0.28%-22.36%-0.14% 12.25B
+2.13%-4.21%-51.63%-68.92% 4.19B
+0.57%+4.02%-22.01%+58.76% 2.78B
-0.65%+6.43%-34.28%-71.67% 1.77B
+1.12%-0.84%-23.32%-12.99% 1.64B
+0.47%-3.59%-36.96%-38.68% 1.57B
+1.47%-0.23%-17.46%-54.38% 1.48B
Average +0.47%+0.37%-13.92%-2.63% 18.13B
Weighted average by Cap. +0.64%-0.46%-10.05%+21.65%

Financials

2026 *2027 *
Net sales 691M 592M 555M 507M 956M 65.86B 966M 6.54B 2.55B 33.23B 2.59B 2.54B 110B 845M 724M 678M 619M 1.17B 80.52B 1.18B 8B 3.11B 40.62B 3.17B 3.1B 135B
Net income -51.88M -44.46M -41.66M -38.05M -71.81M -4.95B -72.52M -491M -191M -2.5B -195M -191M -8.26B 18.93M 16.22M 15.2M 13.88M 26.2M 1.8B 26.45M 179M 69.78M 910M 71.06M 69.52M 3.01B
Net Debt -175M -150M -140M -128M -242M -16.67B -244M -1.66B -645M -8.41B -657M -642M -27.86B -273M -234M -219M -200M -378M -26.01B -381M -2.58B -1.01B -13.12B -1.02B -1B -43.46B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
25/08/26 US$181.39 -2.29% 639,693
24/08/26 US$185.65 +0.41% 622,292
21/08/26 US$184.89 0.00% 440,096
20/08/26 US$184.89 -2.46% 791,869
19/08/26 US$189.55 +2.93% 505,426
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
181.39USD
Average target price
197.15USD
Spread / Average Target
+8.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock